February 2016
Authors:
Ingrid C. Rulifson, Ping Cao, Li Miao, David Kopecky, Linda Huang, Ryan D. White, Kim Samayoa, Jonitha Gardner, Xiaosu Wu, Kui Chen, Trace Tsuruda, Oliver Homann, Helene Baribault, Harvey Yamane, Tim Carlson, Jed Wiltzius, Yang Li
Info:
Researchers from Amgen report on a proteolytic enzyme, BACE2, that could potentially have a therapeutic use for treatment of pancreatic amyloid formation caused by Type-2 diabetes. Illumina RNA-seq, with Pippin size selection, was used to test whether BACE would modulate its target proteins in a cellular setting.
Citation:
PLoS ONE 11(2): e0147254
doi:10.1371/journal.pone.0147254